May 2021 Volume 7 Issue 6

May 2021

Volume 7, Issue 6

This issue provides an update on gene therapies in hematology, demystifies RNA sequencing, and more.

Table of Contents

May 2021 Issue

Editor’s Corner: All Those YESterdays

Saturday, May 1st, 2021
A few weeks ago, I was on a Zoom call with a candidate interviewing for a faculty position. The topic of work-life balance came...
You Make the Call

Reader Responses: Should a mostly asymptomatic patient with amyloidosis receive systemic therapy?

Saturday, May 1st, 2021
Here’s how readers responded to a You Make the Call question about whether a mostly asymptomatic patient with amyloidosis should receive systemic therapy. Disclaimer: ASH...

How Can the Myeloma Community Reduce Disparities in Care?

Saturday, May 1st, 2021
In our March 2021 issue, we reported on findings from a review article examining disparities in outcomes among patients with multiple myeloma (MM), in...

A Day in the Life: Transfusion Medicine as Team Sport

Saturday, May 1st, 2021
In this edition, Justin Kreuter, MD, takes a break from teaching and clinical duties to walk us through a typical day in the life...

May 2021 Issue

Idecabtagene Ciloleucel Induces Deep Responses in Relapsed/Refractory Multiple Myeloma

Saturday, May 1st, 2021
Treatment with the B-cell maturation antigen−targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene ciloleucel (ide-cel) showed encouraging efficacy in patients with heavily pretreated relapsed...

High- and Low-Dose Rivaroxaban Versus Aspirin for Women With VTE and Heavy Menstrual Bleeding

Saturday, May 1st, 2021
Results of a substudy published in Research and Practice in Thrombosis and Haemostasis suggest there is no statistically significant difference in menstrual hemorrhage in...

R2CHOP Benefits Patients With Untreated Diffuse Large B-Cell Lymphoma, Regardless of Subtype

Saturday, May 1st, 2021
For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)...
WIB_icon

Reduced Calf Muscle Pump Function Predicts VTE and Mortality Risk

Saturday, May 1st, 2021
Reduced calf pump function (CPF) appears to be a risk factor for venous thromboembolism (VTE), according to a study published in Blood. In addition,...
WIB_icon

Adding Brentuximab Vedotin to Chemotherapy Improves Outcomes in Pediatric ALK-Positive ALCL

Saturday, May 1st, 2021
The addition of brentuximab vedotin to chemotherapy led to favorable overall survival (OS) and event-free survival (EFS) in children with ALK-positive anaplastic large cell...
WIB_icon

Lenalidomide and Dexamethasone for Older Patients With Multiple Myeloma: Less Is More

Saturday, May 1st, 2021
According to a study published in Blood, older patients with multiple myeloma (MM) who are taking continuous lenalidomide-dexamethasone (Rd) may be able to switch...
The Society Pages

Senate Confirms Surgeon General and Assistant Secretary for Health, HVO Presents Golden Apple Awards,...

Saturday, May 1st, 2021
Brian Bolwell Named Chair of Physician Leadership and Development at Cleveland Clinic The Cleveland Clinic has appointed Brian Bolwell, MD, FACP, as chair of physician...
ASH Directions

ASH Presents FAQ Resource for Thrombosis with Thrombocytopenia, ASH News Daily Seeks 2021 Authors,...

Saturday, May 1st, 2021
New COVID-19 Resource: FAQ About Thrombosis with Thrombocytopenia Syndrome The American Society of Hematology (ASH) has released a resource to guide clinicians in recognizing and...
WIB_icon

Outcomes After ABO-Incompatible Platelet Transfusions in Patients With Intracerebral Hemorrhage

Saturday, May 1st, 2021
For patients with intracerebral hemorrhage (ICH) who received an acute platelet transfusion within 24 hours of hospital admission, the use of an incompatible platelet...

LentiGlobin Not Linked to Cancer, Scientists Say

Saturday, May 1st, 2021
On February 24, the U.S. Food and Drug Administration (FDA) placed a clinical hold on all LentiGlobin gene therapy trials following an announcement that two participants with...

Detection of Platelet-Activating Antibodies Necessary to Diagnose HIT in Patients With COVID-19

Saturday, May 1st, 2021
While high titer anti-PF4/heparin antibodies can often confirm a diagnosis of heparin-induced thrombocytopenia (HIT) and predict a positive platelet activation test in most patients,...

FDA to Reevaluate Six Accelerated Approvals of Cancer Treatments

Saturday, May 1st, 2021
The FDA held a public meeting of its Oncologic Drugs Advisory Committee in late April to reevaluate six treatments that were previously granted accelerated...

Characterizing Complications Among Infants and Toddlers With von Willebrand Disease

Saturday, May 1st, 2021
A new report published in Blood Advances describes the experiences of infants and toddlers living with von Willebrand disease (VWD), highlighting the role and...

FDA Deputy Commissioner and CIO Amy Abernethy Resigns

Saturday, May 1st, 2021
Amy Abernethy, MD, PhD, has announced her resignation from her roles as principal deputy commissioner and acting chief information officer at the FDA. Two years...

Idecabtagene Vicleucel Approved for Relapsed or Refractory Multiple Myeloma

Saturday, May 1st, 2021
The FDA has approved idecabtagene vicleucel (ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy for the treatment of...

May 2021 Issue

Gene Therapy: The Comeback Kid of Hematology Treatments?

Saturday, May 1st, 2021
Despite slow progress and unexpected setbacks, the future of gene therapy remains bright. Ashanthi de Silva was the first human to be treated successfully with...

Pulling Back the Curtain: Craig Cole, MD

Saturday, May 1st, 2021
In this edition, Craig Cole, MD, speaks about empowering patients to make treatment decisions, targeting racial disparities in myeloma, and more. Where did you grow...

May 2021 Issue

You Make the Call

You Make the Call: Should a mostly asymptomatic patient with amyloidosis receive systemic therapy?

Saturday, May 1st, 2021
This month Morie A. Gertz, MD, discusses whether a mostly asymptomatic patient with amyloidosis should receive systemic therapy. And don't forget to check out next...

Unlocking Applications for RNA Sequencing

Saturday, May 1st, 2021
RNA sequencing is a genomics technology that gives scientists a transcriptome-wide view of gene expression and messenger RNA (mRNA) splicing. The tool is already...

Hemophagocytic Lymphohistiocytosis: Would You Know It if You Saw It?

Saturday, May 1st, 2021
Hemophagocytic lymphohistiocytosis (HLH) is a rare disorder in which histiocytes and lymphocytes create a hyperinflammatory response that damages multiple organs.1 People with HLH can...

May 2021 Issue

On location

PATHFINDER: Avapritinib Induces Rapid Responses in Advanced Systemic Mastocytosis

Saturday, May 1st, 2021
Three-quarters of patients with advanced systemic mastocytosis (SM) responded to treatment with the oral KIT D816V inhibitor avapritinib, according to interim results from the...
On location

Evaluating a New Bispecific CAR T-Cell Therapy for B-Cell Lymphomas

Saturday, May 1st, 2021
In a first-in-human phase I clinical trial of a bispecific anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy, four of five treated patients with lymphoma...
On location

Copanlisib Plus Rituximab Improves Progression-Free Survival in Indolent Non-Hodgkin Lymphoma

Saturday, May 1st, 2021
Combining copanlisib with rituximab reduced the risk of progression or death by 48%, compared with placebo plus rituximab, in patients with relapsed advanced indolent...